Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib observational study in advanced gastrointestinal stromal tumor with complex KIT/PDGFRA mutations
ChiCTR2100052208Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR2100052208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052208.